オプションチェーンは、iRadimedの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、iRadimedの市場センチメントを評価します。.

iRadimed (NASDAQ:IRMD) 株価情報, オプションチェーン

iRadimed

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

iRadimed Corp

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) is looking for Q2 Adj EPS of $0.41-$0.44 vs $0.43 analyst estimate. sees sales of $19.700 million-$19.900 million vs $19.81 million analyst estimate.

News

Guidance

IRMD

iRadimed Sees Q2 Adj EPS $0.41-$0.44 vs $0.43 Est; Sees Sales $19.700M-$19.900M vs $19.81M Est

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) affirms FY2025 GAAP EPS guidance from $1.55-$1.65 to $1.55-$1.65 vs $1.64 analyst estimate..

iRadimed Affirms FY2025 GAAP EPS Guidance of $1.55-$1.65 vs $1.64 Est

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) is looking for Q2 GAAP EPS of $0.37-$0.40 vs $0.41 analyst estimate..

iRadimed Sees Q2 GAAP EPS $0.37-$0.40 vs $0.41 Est

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) affirms FY2025 Adj EPS guidance from $1.71-$1.81 to $1.71-$1.81 vs $1.75 analyst estimate. Affirms FY2025 sales outlook from $78.00 million-$82.00 million to $78.00 million-$82.00 million vs $79.41 million estimate.

iRadimed Affirms FY2025 Adj EPS Guidance of $1.71-$1.81 vs $1.75 Est; Affirms FY2025 Sales Guidance of $78.00M-$82.00M vs $79.41M Est

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.41 by 2.44 percent. This is a 16.67 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $19.51 million which beat the analyst consensus estimate of $19.33 million by 0.93 percent. This is a 10.87 percent increase over sales of $17.60 million the same period last year.

Earnings

Earnings Beats

iRadimed Q1 Adj. EPS $0.42 Beats $0.41 Estimate, Sales $19.51M Beat $19.33M Estimate

ACEL

ADEA

ADUS

AESI

AMRC

AOMR

AORT

ARES

AROC

AXSM

BCRX

BCSF

BFAM

BNTX

BRBR

BRCC

BWXT

CERT

CORT

CRBG

CRGY

CSTL

CTRA

DENN

DMRC

DORM

EKSO

ESCA

EVER

FANG

FRPT

GBDC

GECC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSIC

HSII

HSTM

IART

ICHR

INSP

IPAR

JBTM

JELD

JRVR

LSCC

MATX

MYPS

NBIX

NGVT

NMFC

NSSC

NVTS

OCUL

OPAD

OTTR

PLMR

PLOW

PLTR

PLYA

PRAA

PRIM

RAIL

RAND

Earnings Scheduled For May 5, 2025

Roth MKM analyst Jason Wittes reiterates iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) with a Buy and raises the price target from $60 to $72.

Price Target

Reiteration

Analyst Ratings

Roth MKM Reiterates Buy on iRadimed, Raises Price Target to $72

WIIM

Iradimed shares are trading lower. The company reported Q4 financial results.

Health Care

General

Iradimed Expects 2025 Revenue Of $78M-$82M Versus Consensus Of $80.66M, With Adjusted EPS Of $1.71-$1.81 Versus Consensus Of $1.75

Iradimed Expects Q1 2025 Revenue Of $19.2M-$19.4M Versus Consensus Of $19.13M, With Adjusted EPS Of $0.39-$0.43 Versus Consensus Of $0.41

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) reported quarterly earnings of $0.44 per share which met the analyst consensus estimate. This is a 12.82 percent increase over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $19.39 million which beat the analyst consensus estimate of $19.14 million by 1.28 percent. This is a 11.10 percent increase over sales of $17.45 million the same period last year.

iRadimed Q4 2024 Adj EPS $0.44, Inline, Sales $19.39M Beat $19.14M Estimate

ABNB

AENT

AGIO

ALNY

AMAT

APDN

ATUS

AVNT

BENF

BLIN

BPMC

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

COIN

CROX

CYBR

DDOG

DKNG

DNOW

DXCM

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

IRADIMED Reports Prelim. Q4 Revenue $19.2M-$19.4M, Prelim. FY24 Revenue $73.1M-$73.3M

On December 3, a recent SEC filing unveiled that John Glenn, Chief Financial Officer at iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) made an insider sell.
What Happened: Glenn's recent move involves selling 2,500 shares of iRadimed. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001325618/000141588924028036//Archives/edgar/data/1325618/000141588924028036/0001415889-24-028036-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value is $135,449.
iRadimed's shares are actively trading at $53.84, experiencing a down of 0.0% during Tuesday's morning session.
<h3>All You Need to Know About iRadimed</h3>
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
<h3>Financial Insights: iRadimed</h3>
Positive Revenue Trend: Examining iRadimed's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.04% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: With a high gross margin of 77.44%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): iRadimed's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.4.
</li>
</ul>
Debt Management: iRadimed's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: iRadimed's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 36.87.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 9.63, iRadimed's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 28.48, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Cracking Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001325618">Check Out The Full List Of iRadimed's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

iRadimed Chief Financial Officer Sold $135K In Company Stock

For the full year of 2024, the Company expects to report revenue of&nbsp;$72.7 million&nbsp;to&nbsp;$73.1 million, GAAP diluted earnings per share of&nbsp;$1.49&nbsp;to&nbsp;$1.52, and Non-GAAP diluted earnings per share of&nbsp;$1.64&nbsp;to&nbsp;$1.67.

IRadimed Raised FY24 Adj EPS To $1.64 -$1.67 From $1.52 -$1.62 (Vs $1.56 Est.); Revenue To $72.7M-$73.1M From $$72M-$74M Vs $72.62M Est.

IRadimed Sees Q4 EPS $0.42-$0.45 Vs $0.39 Est.; Revenue $18.8M-$19.2M Vs $18.098M Est

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.39 by 10.26 percent. The company reported quarterly sales of $18.326 million which beat the analyst consensus estimate of $18.098 million by 1.26 percent. This is a 11.04 percent increase over sales of $16.505 million the same period last year.

iRadimed Q3 2024 Adj. EPS $0.43 Beats $0.39 Estimate, Sales $18.326M Beat $18.098M Estimate

The healthcare technology sector is undergoing a transformation, with companies leveraging AI, telemedicine, and digital platforms to innovate the way care is delivered. As demand for more efficient and patient-centric solutions grows, several public companies have emerged as leaders in this space.&nbsp;
<h3>1. Teladoc Health</h3>
Market Cap: $1.4 Billion
Focus Area: Telehealth&nbsp;
Teladoc Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>) is a household name in telemedicine and virtual care, offering services in over 175 countries. As one of the pioneers of telehealth, Teladoc has continuously innovated its sm&nbsp; &nbsp; ervices, making healthcare more accessible and convenient. Its acquisition of Livongo, a leader in managing chronic conditions through AI and digital tools, has expanded its capabilities to cover a wide range of health conditions, from diabetes to hypertension.
What Teladoc does best is delivering a seamless virtual care experience across multiple specialties. The company also excels at integrating behavioral health services, allowing patients to receive both physical and mental healthcare from the comfort of their homes. Teladoc&rsquo;s robust data analytics and AI capabilities offer personalized treatment plans, making it one of the most comprehensive telehealth platforms available. With the global demand for virtual healthcare services on the rise, Teladoc&rsquo;s long-term growth prospects are strong.
<h3>2. WELL Health Technologies</h3>
Market Cap: $1.1 Billion
Focus Area: Digital Health Solutions&nbsp;
WELL Health Technologies (TSX: WELL) has become a key player in North America&#39;s digital healthcare market. Known for its extensive acquisition strategy, WELL has rapidly expanded its network of clinics and digital healthcare platforms. What sets WELL apart is its ability to integrate physical and virtual care through telemedicine, while also providing digital health solutions to clinics across Canada and the U.S.&nbsp;
WELL&#39;s partnership with Healwell AI is one of its most recent innovations, using AI to enhance clinical workflows, improve diagnosis accuracy, and optimize patient outcomes. This integration of AI into routine care is positioning WELL as a leader in AI-driven healthcare. Its platform also powers Wisp, a digital health solution that focuses on sexual and reproductive health, catering to underserved demographics, which further diversifies WELL&#39;s service offerings. As digital healthcare adoption increases, WELL&rsquo;s growth trajectory looks promising.
<h3>3. Omnicell</h3>
Market Cap: $1.9 Billion
Focus Area: Automation and analytics
Omnicell (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) is a leader in automated medication management solutions, offering a range of products that streamline pharmacy operations and enhance medication adherence. Its offerings include advanced robotics, software solutions, and AI-powered analytics aimed at improving the accuracy and efficiency of drug dispensing in hospitals and clinics.
What Omnicell excels at is its ability to integrate automation with real-time data analytics. The company&rsquo;s solutions help healthcare providers reduce medication errors, optimize inventory management, and ensure regulatory compliance, ultimately improving patient safety. Omnicell&rsquo;s recent shift toward cloud-based, subscription-driven software services is expected to fuel recurring revenue growth, making it an attractive long-term investment. With automation playing a critical role in the future of healthcare, Omnicell is well-positioned to thrive.
<h3>4. IRadimed Corporation&nbsp;</h3>
Market Cap: $700 Million
Focus Area: MRI-Compatible Devices
IRadimed (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irmd#NASDAQ">IRMD</a>) is pioneering in the MRI-compatible medical device space, addressing the safety challenges posed by traditional equipment in MRI environments. Their MRI-compatible infusion pumps and patient monitoring systems are designed to function safely without causing electromagnetic interference. This focus on MRI-specific safety is a niche yet crucial aspect of patient care, as it allows for uninterrupted and safer patient management during MRI procedures.
With increased utilization of MRI procedures in diagnostics, IRadimed&rsquo;s specialized products are seeing growing demand. The company is expanding its product lineup and entering new geographic markets, which positions it for sustained growth. IRadimed&rsquo;s focus on high-margin, niche products gives it a competitive advantage, contributing to steady revenue growth and profitability.
<h3>5. Evolent Health Inc.</h3>
Market Cap: $1.3 Billion
Focus Area: Value-Based Care
Evolent Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) specializes in helping healthcare providers transition to value-based care models, which prioritize patient outcomes over service volume. By offering integrated clinical and administrative services, Evolent enables providers to focus on patient care while optimizing operational efficiencies. Their unique approach is centered on a data-driven platform called Identifi, which uses predictive analytics to guide care decisions and minimize costly interventions.
With the shift in the U.S. healthcare system towards value-based models, Evolent has positioned itself as a leader in this space. As more healthcare systems adopt this model, Evolent&rsquo;s solutions are likely to be in high demand. The company has been expanding through strategic partnerships and acquisitions, projecting steady revenue growth in the coming years.
<h3>6. CareDx, Inc.</h3>
Market Cap: $520 Million
Focus Area: Transplant Diagnostics
CareDx (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdna#NASDAQ">CDNA</a>) specializes in providing precision diagnostics for transplant patients, focusing on improving graft survival rates. Their flagship product, AlloSure, is a non-invasive blood test that monitors donor-derived cell-free DNA, enabling early detection of organ rejection. By leveraging genomics and data analytics, CareDx offers a personalized approach that minimizes the need for biopsies and improves patient outcomes.
CareDx is positioned for growth as demand for non-invasive diagnostic solutions rises, particularly in the transplant community. The company is continually enhancing its testing solutions and expanding its presence in international markets. Although competition is intensifying, CareDx&rsquo;s innovative pipeline and established reputation should support long-term growth.
<h3>7. Tactile Systems Technology, Inc.</h3>
Market Cap: $450 Million
Focus Area: Chronic Disease Management
Tactile Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcmd#NASDAQ">TCMD</a>) is addressing the problem of lymphedema and chronic swelling conditions, which often go underdiagnosed and undertreated. Their flagship product, the Flexitouch System, is a pneumatic compression device designed for at-home use, giving patients a non-invasive option for managing their symptoms. The company&#39;s focus on patient education and therapy adherence further differentiates it from competitors.
Tactile Medical has a robust market opportunity, given the growing prevalence of chronic diseases and the increased emphasis on at-home healthcare solutions. Despite recent headwinds due to reimbursement challenges, the company is expanding its product portfolio and expects growth as new regulatory changes potentially improve reimbursement rates.
<h4>Conclusion:</h4>
the healthcare technology sector is experiencing significant transformation driven by advancements in AI, telemedicine, and digital solutions. These innovations are reshaping how care is delivered, making it more efficient and patient-centric. As the demand for enhanced healthcare experiences grows, the industry is poised to improve outcomes and accessibility. Looking toward 2025, the ongoing evolution in this field will be critical in addressing the challenges facing healthcare systems worldwide.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Small Cap

CDNA

OMCL

TCMD

TDOC

Future Forward: 7 Groundbreaking Healthcare Technology Companies Poised To Disrupt the Industry By 2025

Roth MKM analyst Jason Wittes maintains iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) with a Buy and lowers the price target from $65 to $60.

Roth MKM Maintains Buy on iRadimed, Lowers Price Target to $60

"Looking ahead to the year's second half, we are confident in maintaining our strong financial performance. For the third quarter of 2024, we anticipate revenue of $18.0 million to $18.2 million, GAAP diluted earnings per share of $0.34 to $0.37, and non-GAAP diluted earnings per share of $0.38 to $0.41. We reiterate our guidance for the year, expecting to report revenue of $72.0 million to $74.0 million, GAAP diluted earnings per share of $1.37 to $1.47, and non-GAAP diluted earnings per share of $1.52 to $1.62," added Mr. Susi.&nbsp;

IRadimed Sees Q3 EPS $0.38-$0.41 Vs $0.37 Est.; Revenue $18M-$18.2M Vs $17.7M Est. Reiterates FY24 EPS Of $1.52-$1.62 Vs $1.53 Est.; Revenue $72M-$74M Vs $72.29M Est.

Press Releases

IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024

IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025

IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference

IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues

IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025

IRADIMED CORPORATION Announces Fourth Quarter and Full Year of 2024 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.17 Per Share from $0.15 Per Share

IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference

IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

Comments

iRadimed

iRadimed (IRMD) オプション

iRadimed (NASDAQ:IRMD) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル